IL6 and endothelial dysfunction: In line with this finding, the use of TNF-α inhibitors in patients with a high level of inflammation, such as rheumatoid arthritis, decreased atherosclerotic CV events similarly to the use of IL-6 blockers [43], also improving the endothelial dysfunction [24].